HK1258611A1 - 腹水的治疗 - Google Patents

腹水的治疗 Download PDF

Info

Publication number
HK1258611A1
HK1258611A1 HK19100970.3A HK19100970A HK1258611A1 HK 1258611 A1 HK1258611 A1 HK 1258611A1 HK 19100970 A HK19100970 A HK 19100970A HK 1258611 A1 HK1258611 A1 HK 1258611A1
Authority
HK
Hong Kong
Prior art keywords
ascites
continuous infusion
treatment
patients
terlipressin
Prior art date
Application number
HK19100970.3A
Other languages
English (en)
Chinese (zh)
Inventor
Paolo Angeli
Penelope MARKHAM
Jonathan Adams
Original Assignee
Biovie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1258611(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovie Inc. filed Critical Biovie Inc.
Publication of HK1258611A1 publication Critical patent/HK1258611A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HK19100970.3A 2015-06-30 2016-06-30 腹水的治疗 HK1258611A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12
PCT/US2016/040284 WO2017004317A1 (en) 2015-06-30 2016-06-30 Treatment of ascites

Publications (1)

Publication Number Publication Date
HK1258611A1 true HK1258611A1 (zh) 2019-11-15

Family

ID=57609113

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100970.3A HK1258611A1 (zh) 2015-06-30 2016-06-30 腹水的治疗

Country Status (7)

Country Link
US (6) US9655945B2 (enExample)
EP (2) EP3347032B1 (enExample)
JP (6) JP2017014206A (enExample)
CN (2) CN120324576A (enExample)
ES (1) ES2971959T3 (enExample)
HK (1) HK1258611A1 (enExample)
WO (1) WO2017004317A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032140A2 (en) 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
PT3978074T (pt) 2014-10-24 2024-05-13 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressina para tratamento da síndrome hepatorrenal de tipo 1
FI3253401T3 (fi) 2015-02-03 2025-07-09 Amryt Endo Inc Akromegallian hoitaminen suun kautta annettavalla oktreotidilla
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
MA46586A (fr) 2016-10-21 2019-08-28 Chiasma Inc Compositions de terlipressine et leurs procédés d'utilisation
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
JP2025505010A (ja) * 2022-02-03 2025-02-19 バイオビー インコーポレーテッド テルリプレシンを用いた疾患の治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) * 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
HUE027174T2 (en) * 2006-02-13 2016-10-28 Ferring Bv Use of peptide agonists of the vasopressin receptor
EP2175874A2 (en) * 2007-08-14 2010-04-21 Ferring B.V. Use of peptidic vasopressin receptor agonists
US20100311642A1 (en) * 2007-09-28 2010-12-09 Ferring B.V. Use of v2 receptor antagonists in combination with vaso pressinergic agnosts
US20110003890A1 (en) * 2007-11-08 2011-01-06 Jason Joel Schwartz Use of angiogenesis antagonists in conditions of abnormal venous proliferation
US8815232B2 (en) * 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
ES2661310T3 (es) * 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
EA025735B1 (ru) * 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
WO2013106072A1 (en) * 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CN102731625B (zh) * 2012-06-27 2014-10-15 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法
US9091701B2 (en) 2012-11-12 2015-07-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
JP6522584B2 (ja) * 2013-04-26 2019-05-29 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎不全を処置するための組成物及び方法
CN104510840A (zh) * 2013-08-21 2015-04-15 乔治亚摄政研究学院有限公司 改性绿茶多酚和其用于治疗肝病的方法
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
ES2971959T3 (es) 2024-06-10
CN120324576A (zh) 2025-07-18
CN106999539A (zh) 2017-08-01
JP2018172440A (ja) 2018-11-08
US11364277B2 (en) 2022-06-21
WO2017004317A1 (en) 2017-01-05
JP2023160839A (ja) 2023-11-02
US20230146264A1 (en) 2023-05-11
JP2025143324A (ja) 2025-10-01
JP2022136104A (ja) 2022-09-15
JP2017014206A (ja) 2017-01-19
US20190365848A1 (en) 2019-12-05
US20180000887A1 (en) 2018-01-04
US20240165193A1 (en) 2024-05-23
US20170000844A1 (en) 2017-01-05
EP4338795A2 (en) 2024-03-20
JP2020172520A (ja) 2020-10-22
US20250312410A1 (en) 2025-10-09
EP3347032A1 (en) 2018-07-18
US9655945B2 (en) 2017-05-23
EP3347032B1 (en) 2023-11-29
EP3347032A4 (en) 2019-06-19
EP4338795A3 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
HK1258611A1 (zh) 腹水的治疗
CA187580S (en) Administration set for infusion pump
IL263670A (en) Assemblies and methods for infusion pump system delivery kits
IL270715A (en) Cannula for intravascular blood pump
WO2012115772A3 (en) Therapy for kidney disease and/or heart failure
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
MX2018004834A (es) Metodos para tratar dolor usando dimeros de acetominofeno farmaceuticamente activos enlazados a traves de grupos hidroxilo fenolicos.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
IL275282A (en) Infusion pump systems and methods for administration kits
MX391926B (es) Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto.
EP3256133A4 (en) Intravenous infusion dosage form
EP3305347A4 (en) LIQUID INFUSION DEVICE FOR MEDICINE ADMINISTRATION TO A PATIENT
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
TN2017000292A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
MX2016011881A (es) Medicamento de peptido en polvo seco.
HK1254855A1 (zh) 在手术期间给患者静脉内施用瓜氨酸
EP3174574A4 (en) Medicament infusion system and pump assembly for use therein
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
HK1259373A1 (zh) 用於治疗糖尿病的药物制剂
HK1226581A1 (zh) 用於输液器上的过滤器
EP3225267A4 (en) Drug administration mechanism, method for using drug administration mechanism, and pump unit for drug administration mechanism
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
WO2014149998A8 (en) Systemic administration of androgen in treating dry eye syndrome